Related Experiment Video

Updated: Jun 6, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

PI-3-Kinase inhibitors in colorectal cancer

N T Ihle1, G Powis, S Kopetz

  • 1University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Current Cancer Drug Targets
|December 17, 2010
PubMed

Insights

Targeting PI-3-Kinase/AKT signaling shows promise for metastatic colorectal cancer. Success depends on identifying responsive patients and optimizing treatment combinations for personalized medicine.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic colorectal cancer (mCRC) remains challenging to treat effectively.
  • The PI-3-Kinase/AKT signaling pathway is crucial for colorectal tumor growth and survival.
  • Preclinical data suggest PI-3-Kinase inhibitors are potential therapeutics for mCRC.

Purpose of the Study:

  • To review the potential of PI-3-Kinase inhibitors in treating metastatic colorectal cancer.
  • To discuss strategies for patient stratification and biomarker monitoring for PI-3-Kinase inhibitor therapy.
  • To explore optimal combination strategies for PI-3-Kinase inhibitors with existing and emerging therapies.

Main Methods:

  • Review of preclinical studies on PI-3-Kinase/AKT pathway inhibitors in colorectal cancer.
  • Analysis of clinical trial progress for PI-3-Kinase inhibitors.
  • Discussion of biomarker-driven patient selection and treatment personalization.

Main Results:

  • Numerous PI-3-Kinase inhibitors are advancing through early clinical trials.
  • Patient selection based on predictive biomarkers is critical for therapeutic success, mirroring EGFR inhibitor strategies.
  • Effective monitoring of biomarkers and patient response is essential for evaluating PI-3-Kinase inhibitors.

Conclusions:

  • The clinical success of PI-3-Kinase inhibitors in mCRC hinges on precise patient stratification.
  • Combining PI-3-Kinase inhibitors with other therapies requires careful consideration of efficacy and toxicity.
  • These agents represent a significant step towards achieving personalized medicine in colorectal cancer treatment.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...